PAG
IMDX

Private Advisor Group’s Insight Molecular Diagnostics IMDX Stock Holding History

Private Advisor Group’s Portfolio IMDX Stock Details IMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$34.2K Hold
10,416
– – ﹤0.01% 2599
2025
Q4 		$78.1K Hold
10,416
– – ﹤0.01% 2495
2025
Q3 		$34.6K Buy
+10,416
New +$29.4K ﹤0.01% 2472

Other funds holding IMDX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
HCM
Heights Capital Management San Francisco, California $359M AUM 7.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Private Advisor Group's IMDX Position: Q1 2026 in Review

Private Advisor Group held its Insight Molecular Diagnostics (IMDX) position steady in Q1 2026 at 10,416 shares worth $34.2K. The position accounts for ﹤0.01% of the portfolio, ranked #2599.

Private Advisor Group first reported a position in IMDX in Q3 2025 and has held it in 3 quarters since. The position peaked at $78.1K in Q4 2025. 41 funds tracked by Wall St. Rank hold IMDX as of Q1 2026.

  • Private Advisor Group held 10,416 shares of Insight Molecular Diagnostics worth $34.2K as of Q1 2026.
  • Private Advisor Group left its Insight Molecular Diagnostics share count unchanged in Q1 2026.
  • Insight Molecular Diagnostics made up ﹤0.01% of Private Advisor Group's portfolio in Q1 2026, its #2599 holding.
  • Private Advisor Group first reported a position in Insight Molecular Diagnostics in Q3 2025 and has held it in 3 quarters since.
  • Private Advisor Group's Insight Molecular Diagnostics position peaked at $78.1K in Q4 2025.
  • 41 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q1 2026.

Based on Private Advisor Group's 13F filing for Q1 2026, filed 27 Apr 2026.